Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Vély F[au]:

Innate lymphoid cells: major players in inflammatory diseases. Ebbo M et al. Nat Rev Immunol. (2017)

Innate Lymphoid Cells in Cancer. Vallentin B et al. Cancer Immunol Res. (2015)

Evidence of innate lymphoid cell redundancy in humans. Vély F et al. Nat Immunol. (2016)

Search results

Items: 1 to 50 of 66

1.

High-Dimensional Single-Cell Analysis Identifies Organ-Specific Signatures and Conserved NK Cell Subsets in Humans and Mice.

Crinier A, Milpied P, Escalière B, Piperoglou C, Galluso J, Balsamo A, Spinelli L, Cervera-Marzal I, Ebbo M, Girard-Madoux M, Jaeger S, Bollon E, Hamed S, Hardwigsen J, Ugolini S, Vély F, Narni-Mancinelli E, Vivier E.

Immunity. 2018 Nov 20;49(5):971-986.e5. doi: 10.1016/j.immuni.2018.09.009. Epub 2018 Nov 6.

2.

Reply to 'Comment on: Evidence of innate lymphoid cell redundancy in humans'.

Vivier E, Vély F, Fischer A.

Nat Immunol. 2018 Aug;19(8):789-790. doi: 10.1038/s41590-018-0165-4. No abstract available.

PMID:
30026478
3.

Dominant-negative IKZF1 mutations cause a T, B, and myeloid cell combined immunodeficiency.

Boutboul D, Kuehn HS, Van de Wyngaert Z, Niemela JE, Callebaut I, Stoddard J, Lenoir C, Barlogis V, Farnarier C, Vely F, Yoshida N, Kojima S, Kanegane H, Hoshino A, Hauck F, Lhermitte L, Asnafi V, Roehrs P, Chen S, Verbsky JW, Calvo KR, Husami A, Zhang K, Roberts J, Amrol D, Sleaseman J, Hsu AP, Holland SM, Marsh R, Fischer A, Fleisher TA, Picard C, Latour S, Rosenzweig SD.

J Clin Invest. 2018 Jul 2;128(7):3071-3087. doi: 10.1172/JCI98164. Epub 2018 Jun 11.

4.

Combined Immunodeficiency in Patients With Trichohepatoenteric Syndrome.

Vély F, Barlogis V, Marinier E, Coste ME, Dubern B, Dugelay E, Lemale J, Martinez-Vinson C, Peretti N, Perry A, Bourgeois P, Badens C, Goulet O, Hugot JP, Farnarier C, Fabre A.

Front Immunol. 2018 May 11;9:1036. doi: 10.3389/fimmu.2018.01036. eCollection 2018.

5.

Innate lymphoid cells: major players in inflammatory diseases.

Ebbo M, Crinier A, Vély F, Vivier E.

Nat Rev Immunol. 2017 Nov;17(11):665-678. doi: 10.1038/nri.2017.86. Epub 2017 Aug 14. Review.

PMID:
28804130
6.

Shifting the Balance of Activating and Inhibitory Natural Killer Receptor Ligands on BRAFV600E Melanoma Lines with Vemurafenib.

Frazao A, Colombo M, Fourmentraux-Neves E, Messaoudene M, Rusakiewicz S, Zitvogel L, Vivier E, Vély F, Faure F, Dréno B, Benlalam H, Bouquet F, Savina A, Pasmant E, Toubert A, Avril MF, Caignard A.

Cancer Immunol Res. 2017 Jul;5(7):582-593. doi: 10.1158/2326-6066.CIR-16-0380. Epub 2017 Jun 2.

7.

Inherited GINS1 deficiency underlies growth retardation along with neutropenia and NK cell deficiency.

Cottineau J, Kottemann MC, Lach FP, Kang YH, Vély F, Deenick EK, Lazarov T, Gineau L, Wang Y, Farina A, Chansel M, Lorenzo L, Piperoglou C, Ma CS, Nitschke P, Belkadi A, Itan Y, Boisson B, Jabot-Hanin F, Picard C, Bustamante J, Eidenschenk C, Boucherit S, Aladjidi N, Lacombe D, Barat P, Qasim W, Hurst JA, Pollard AJ, Uhlig HH, Fieschi C, Michon J, Bermudez VP, Abel L, de Villartay JP, Geissmann F, Tangye SG, Hurwitz J, Vivier E, Casanova JL, Smogorzewska A, Jouanguy E.

J Clin Invest. 2017 May 1;127(5):1991-2006. doi: 10.1172/JCI90727. Epub 2017 Apr 17.

8.

T Cell Polarization toward TH2/TFH2 and TH17/TFH17 in Patients with IgG4-Related Disease.

Grados A, Ebbo M, Piperoglou C, Groh M, Regent A, Samson M, Terrier B, Loundou A, Morel N, Audia S, Maurier F, Graveleau J, Hamidou M, Forestier A, Palat S, Bernit E, Bonotte B, Farnarier C, Harlé JR, Costedoat-Chalumeau N, Vély F, Schleinitz N.

Front Immunol. 2017 Mar 13;8:235. doi: 10.3389/fimmu.2017.00235. eCollection 2017.

9.

NKp30 isoforms and NKp30 ligands are predictive biomarkers of response to imatinib mesylate in metastatic GIST patients.

Rusakiewicz S, Perier A, Semeraro M, Pitt JM, Pogge von Strandmann E, Reiners KS, Aspeslagh S, Pipéroglou C, Vély F, Ivagnes A, Jegou S, Halama N, Chaigneau L, Validire P, Christidis C, Perniceni T, Landi B, Berger A, Isambert N, Domont J, Bonvalot S, Terrier P, Adam J, Coindre JM, Emile JF, Poirier-Colame V, Chaba K, Rocha B, Caignard A, Toubert A, Enot D, Koch J, Marabelle A, Lambert M, Caillat-Zucman S, Leyvraz S, Auclair C, Vivier E, Eggermont A, Borg C, Blay JY, Le Cesne A, Mir O, Zitvogel L.

Oncoimmunology. 2016 Apr 25;6(1):e1137418. doi: 10.1080/2162402X.2015.1137418. eCollection 2017.

10.

Corrigendum: Evidence of innate lymphoid cell redundancy in humans.

Vély F, Barlogis V, Vallentin B, Neven B, Piperoglou C, Perchet T, Petit M, Yessaad N, Touzot F, Bruneau J, Mahlaoui N, Zucchini N, Farnarier C, Michel G, Moshous D, Blanche S, Dujardin A, Spits H, Distler JH, Ramming A, Picard C, Golub R, Fischer A, Vivier E.

Nat Immunol. 2016 Nov 16;17(12):1479. doi: 10.1038/ni1216-1479b. No abstract available.

PMID:
27849206
11.

Structural Insights into the Inhibitory Mechanism of an Antibody against B7-H6, a Stress-Induced Cellular Ligand for the Natural Killer Cell Receptor NKp30.

Xu X, Narni-Mancinelli E, Cantoni C, Li Y, Guia S, Gauthier L, Chen Q, Moretta A, Vély F, Eisenstein E, Rangarajan S, Vivier E, Mariuzza RA.

J Mol Biol. 2016 Nov 6;428(22):4457-4466. doi: 10.1016/j.jmb.2016.09.011. Epub 2016 Sep 20.

PMID:
27663271
12.

Evidence of innate lymphoid cell redundancy in humans.

Vély F, Barlogis V, Vallentin B, Neven B, Piperoglou C, Ebbo M, Perchet T, Petit M, Yessaad N, Touzot F, Bruneau J, Mahlaoui N, Zucchini N, Farnarier C, Michel G, Moshous D, Blanche S, Dujardin A, Spits H, Distler JH, Ramming A, Picard C, Golub R, Fischer A, Vivier E.

Nat Immunol. 2016 Nov;17(11):1291-1299. doi: 10.1038/ni.3553. Epub 2016 Sep 12. Erratum in: Nat Immunol. 2016 Nov 16;17 (12 ):1479.

13.

PD-1 mediates functional exhaustion of activated NK cells in patients with Kaposi sarcoma.

Beldi-Ferchiou A, Lambert M, Dogniaux S, Vély F, Vivier E, Olive D, Dupuy S, Levasseur F, Zucman D, Lebbé C, Sène D, Hivroz C, Caillat-Zucman S.

Oncotarget. 2016 Nov 8;7(45):72961-72977. doi: 10.18632/oncotarget.12150.

14.

HLA-Fatal attraction.

Vély F, Golub R, Vivier E.

Nat Immunol. 2016 Aug 19;17(9):1012-4. doi: 10.1038/ni.3541. No abstract available.

PMID:
27540985
15.

Low Circulating Natural Killer Cell Counts are Associated With Severe Disease in Patients With Common Variable Immunodeficiency.

Ebbo M, Gérard L, Carpentier S, Vély F, Cypowyj S, Farnarier C, Vince N, Malphettes M, Fieschi C, Oksenhendler E, Schleinitz N, Vivier E; DEFI Study Group.

EBioMedicine. 2016 Apr;6:222-230. doi: 10.1016/j.ebiom.2016.02.025. Epub 2016 Mar 2.

16.

Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC.

Besse B, Charrier M, Lapierre V, Dansin E, Lantz O, Planchard D, Le Chevalier T, Livartoski A, Barlesi F, Laplanche A, Ploix S, Vimond N, Peguillet I, Théry C, Lacroix L, Zoernig I, Dhodapkar K, Dhodapkar M, Viaud S, Soria JC, Reiners KS, Pogge von Strandmann E, Vély F, Rusakiewicz S, Eggermont A, Pitt JM, Zitvogel L, Chaput N.

Oncoimmunology. 2015 Aug 12;5(4):e1071008. eCollection 2016 Apr.

17.

NK cell compartment in the peripheral blood and spleen in adult patients with primary immune thrombocytopenia.

Ebbo M, Audonnet S, Grados A, Benarous L, Mahevas M, Godeau B, Viallard JF, Piperoglou C, Cognet C, Farnarier C, Harlé JR, Schleinitz N, Vély F.

Clin Immunol. 2017 Apr;177:18-28. doi: 10.1016/j.clim.2015.11.005. Epub 2015 Nov 18.

PMID:
26598010
18.

Innate Lymphoid Cells in Cancer.

Vallentin B, Barlogis V, Piperoglou C, Cypowyj S, Zucchini N, Chéné M, Navarro F, Farnarier C, Vivier E, Vély F.

Cancer Immunol Res. 2015 Oct;3(10):1109-14. doi: 10.1158/2326-6066.CIR-15-0222. Review.

19.

Clinical impact of the NKp30/B7-H6 axis in high-risk neuroblastoma patients.

Semeraro M, Rusakiewicz S, Minard-Colin V, Delahaye NF, Enot D, Vély F, Marabelle A, Papoular B, Piperoglou C, Ponzoni M, Perri P, Tchirkov A, Matta J, Lapierre V, Shekarian T, Valsesia-Wittmann S, Commo F, Prada N, Poirier-Colame V, Bressac B, Cotteret S, Brugieres L, Farace F, Chaput N, Kroemer G, Valteau-Couanet D, Zitvogel L.

Sci Transl Med. 2015 Apr 15;7(283):283ra55. doi: 10.1126/scitranslmed.aaa2327.

PMID:
25877893
20.

CD146 mediates VEGF-induced melanoma cell extravasation through FAK activation.

Jouve N, Bachelier R, Despoix N, Blin MG, Matinzadeh MK, Poitevin S, Aurrand-Lions M, Fallague K, Bardin N, Blot-Chabaud M, Vely F, Dignat-George F, Leroyer AS.

Int J Cancer. 2015 Jul 1;137(1):50-60. doi: 10.1002/ijc.29370. Epub 2014 Dec 11.

21.

Causal analysis of H1N1pdm09 influenza infection risk in a household cohort.

Mansiaux Y, Salez N, Lapidus N, Setbon M, Andreoletti L, Leruez-Ville M, Cauchemez S, Gougeon ML, Vély F, Schwarzinger M, Abel L, Delabre RM, Flahault A, de Lamballerie X, Carrat F.

J Epidemiol Community Health. 2015 Mar;69(3):272-7. doi: 10.1136/jech-2014-204678. Epub 2014 Nov 21.

22.

Serum Immunoglobulin Free Light Chain Assessment in IgG4-Related Disease.

Grados A, Ebbo M, Boucraut J, Vély F, Aucouturier P, Rigolet A, Terrier B, Saadoun D, Ghillani-Dalbin P, Costedoat-Chalumeau N, Harlé JR, Schleinitz N.

Int J Rheumatol. 2013;2013:426759. doi: 10.1155/2013/426759. Epub 2013 Jun 26.

23.

Induction of B7-H6, a ligand for the natural killer cell-activating receptor NKp30, in inflammatory conditions.

Matta J, Baratin M, Chiche L, Forel JM, Cognet C, Thomas G, Farnarier C, Piperoglou C, Papazian L, Chaussabel D, Ugolini S, Vély F, Vivier E.

Blood. 2013 Jul 18;122(3):394-404. doi: 10.1182/blood-2013-01-481705. Epub 2013 May 17.

24.

Factors associated with post-seasonal serological titer and risk factors for infection with the pandemic A/H1N1 virus in the French general population.

Lapidus N, de Lamballerie X, Salez N, Setbon M, Delabre RM, Ferrari P, Moyen N, Gougeon ML, Vely F, Leruez-Ville M, Andreoletti L, Cauchemez S, Boëlle PY, Vivier E, Abel L, Schwarzinger M, Legeas M, Le Cann P, Flahault A, Carrat F.

PLoS One. 2013 Apr 16;8(4):e60127. doi: 10.1371/journal.pone.0060127. Print 2013.

25.

Phenotype and functions of natural killer cells in critically-ill septic patients.

Forel JM, Chiche L, Thomas G, Mancini J, Farnarier C, Cognet C, Guervilly C, Daumas A, Vély F, Xéridat F, Vivier E, Papazian L.

PLoS One. 2012;7(12):e50446. doi: 10.1371/journal.pone.0050446. Epub 2012 Dec 6.

26.

The involvement of CD146 and its novel ligand Galectin-1 in apoptotic regulation of endothelial cells.

Jouve N, Despoix N, Espeli M, Gauthier L, Cypowyj S, Fallague K, Schiff C, Dignat-George F, Vély F, Leroyer AS.

J Biol Chem. 2013 Jan 25;288(4):2571-9. doi: 10.1074/jbc.M112.418848. Epub 2012 Dec 7.

27.

Interferon-γ production by natural killer cells and cytomegalovirus in critically ill patients.

Chiche L, Forel JM, Thomas G, Farnarier C, Cognet C, Guervilly C, Zandotti C, Vély F, Roch A, Vivier E, Papazian L.

Crit Care Med. 2012 Dec;40(12):3162-9. doi: 10.1097/CCM.0b013e318260c90e.

PMID:
22971588
28.

Pathologies Associated with Serum IgG4 Elevation.

Ebbo M, Grados A, Bernit E, Vély F, Boucraut J, Harlé JR, Daniel L, Schleinitz N.

Int J Rheumatol. 2012;2012:602809. doi: 10.1155/2012/602809. Epub 2012 Aug 26.

29.

Integrative study of pandemic A/H1N1 influenza infections: design and methods of the CoPanFlu-France cohort.

Lapidus N, de Lamballerie X, Salez N, Setbon M, Ferrari P, Delabre RM, Gougeon ML, Vely F, Leruez-Ville M, Andreoletti L, Cauchemez S, Boëlle PY, Vivier E, Abel L, Schwarzinger M, Legeas M, Le Cann P, Flahault A, Carrat F.

BMC Public Health. 2012 Jun 7;12:417. doi: 10.1186/1471-2458-12-417.

30.

Tuning of natural killer cell reactivity by NKp46 and Helios calibrates T cell responses.

Narni-Mancinelli E, Jaeger BN, Bernat C, Fenis A, Kung S, De Gassart A, Mahmood S, Gut M, Heath SC, Estellé J, Bertosio E, Vely F, Gastinel LN, Beutler B, Malissen B, Malissen M, Gut IG, Vivier E, Ugolini S.

Science. 2012 Jan 20;335(6066):344-8. doi: 10.1126/science.1215621.

31.

[IgG4-related systemic disease: emergence of a new systemic disease? Literature review].

Ebbo M, Grados A, Daniel L, Vély F, Harlé JR, Pavic M, Schleinitz N.

Rev Med Interne. 2012 Jan;33(1):23-34. doi: 10.1016/j.revmed.2011.08.012. Epub 2011 Sep 28. Review. French.

PMID:
21955722
32.

The role of natural killer cells in sepsis.

Chiche L, Forel JM, Thomas G, Farnarier C, Vely F, Bléry M, Papazian L, Vivier E.

J Biomed Biotechnol. 2011;2011:986491. doi: 10.1155/2011/986491. Epub 2011 May 14. Review.

33.

Natural killer cells in human autoimmune diseases.

Schleinitz N, Vély F, Harlé JR, Vivier E.

Immunology. 2010 Dec;131(4):451-8. doi: 10.1111/j.1365-2567.2010.03360.x. Epub 2010 Oct 13. Review.

34.

CD146 short isoform increases the proangiogenic potential of endothelial progenitor cells in vitro and in vivo.

Kebir A, Harhouri K, Guillet B, Liu JW, Foucault-Bertaud A, Lamy E, Kaspi E, Elganfoud N, Vely F, Sabatier F, Sampol J, Pisano P, Kruithof EK, Bardin N, Dignat-George F, Blot-Chabaud M.

Circ Res. 2010 Jul 9;107(1):66-75. doi: 10.1161/CIRCRESAHA.109.213827. Epub 2010 May 6.

PMID:
20448216
35.

Soluble CD146 displays angiogenic properties and promotes neovascularization in experimental hind-limb ischemia.

Harhouri K, Kebir A, Guillet B, Foucault-Bertaud A, Voytenko S, Piercecchi-Marti MD, Berenguer C, Lamy E, Vely F, Pisano P, Ouafik L, Sabatier F, Sampol J, Bardin N, Dignat-George F, Blot-Chabaud M.

Blood. 2010 May 6;115(18):3843-51. doi: 10.1182/blood-2009-06-229591. Epub 2010 Feb 25.

36.

Pattern of DAP12 expression in leukocytes from both healthy and systemic lupus erythematosus patients.

Schleinitz N, Chiche L, Guia S, Bouvier G, Vernier J, Morice A, Houssaint E, Harlé JR, Kaplanski G, Montero-Julian FA, Vély F.

PLoS One. 2009 Jul 16;4(7):e6264. doi: 10.1371/journal.pone.0006264.

37.

CD146 and its soluble form regulate monocyte transendothelial migration.

Bardin N, Blot-Chabaud M, Despoix N, Kebir A, Harhouri K, Arsanto JP, Espinosa L, Perrin P, Robert S, Vely F, Sabatier F, Le Bivic A, Kaplanski G, Sampol J, Dignat-George F.

Arterioscler Thromb Vasc Biol. 2009 May;29(5):746-53. doi: 10.1161/ATVBAHA.108.183251. Epub 2009 Feb 19.

PMID:
19229070
38.

Mouse CD146/MCAM is a marker of natural killer cell maturation.

Despoix N, Walzer T, Jouve N, Blot-Chabaud M, Bardin N, Paul P, Lyonnet L, Vivier E, Dignat-George F, Vély F.

Eur J Immunol. 2008 Oct;38(10):2855-64. doi: 10.1002/eji.200838469.

39.

Reciprocal regulation of human natural killer cells and macrophages associated with distinct immune synapses.

Nedvetzki S, Sowinski S, Eagle RA, Harris J, Vély F, Pende D, Trowsdale J, Vivier E, Gordon S, Davis DM.

Blood. 2007 May 1;109(9):3776-85. Epub 2007 Jan 11.

40.

Distribution of killer-cell immunoglobulin-like receptor (KIR) in Comoros and Southeast France.

Frassati C, Touinssi M, Picard C, Segura M, Galicher V, Papa K, Gagne K, Vivier E, Degioanni A, Böetsch G, Mercier P, Vély F, de Micco P, Reviron D, Chiaroni J.

Tissue Antigens. 2006 May;67(5):356-67.

PMID:
16671942
41.

[NK cells: new insights on physiology and clinical implication in diseases].

Schleinitz N, Hamidou M, Vély F, Paul P, Figarella-Branger D, Kaplanski G, Dignat-George F, Vivier E, Harlé JR.

Rev Med Interne. 2006 Jun;27(6):465-72. Epub 2005 Dec 9. Review. French.

PMID:
16368165
42.

Recognition of peptide-MHC class I complexes by activating killer immunoglobulin-like receptors.

Stewart CA, Laugier-Anfossi F, Vély F, Saulquin X, Riedmuller J, Tisserant A, Gauthier L, Romagné F, Ferracci G, Arosa FA, Moretta A, Sun PD, Ugolini S, Vivier E.

Proc Natl Acad Sci U S A. 2005 Sep 13;102(37):13224-9. Epub 2005 Sep 2.

43.

Natural killer cell receptor signaling pathway in mammals.

Vély F, Vivier E.

Sci STKE. 2005 Jul 12;2005(292):cm7.

44.

Natural killer cell receptor signaling pathway.

Vély F, Vivier E.

Sci STKE. 2005 Jul 12;2005(292):cm6.

45.

Coordination of activating and inhibitory signals in natural killer cells.

Chiesa S, Tomasello E, Vivier E, Vély F.

Mol Immunol. 2005 Feb;42(4):477-84. Review. Erratum in: Mol Immunol. 2005 Apr;42(6):743-6.

PMID:
15607802
46.

Natural killer cell signaling pathways.

Vivier E, Nunès JA, Vély F.

Science. 2004 Nov 26;306(5701):1517-9.

PMID:
15567854
47.

Homophilic interaction of NTBA, a member of the CD2 molecular family: induction of cytotoxicity and cytokine release in human NK cells.

Falco M, Marcenaro E, Romeo E, Bellora F, Marras D, Vély F, Ferracci G, Moretta L, Moretta A, Bottino C.

Eur J Immunol. 2004 Jun;34(6):1663-72.

48.

Critical role of Src and SHP-2 in sst2 somatostatin receptor-mediated activation of SHP-1 and inhibition of cell proliferation.

Ferjoux G, Lopez F, Esteve JP, Ferrand A, Vivier E, Vely F, Saint-Laurent N, Pradayrol L, Buscail L, Susini C.

Mol Biol Cell. 2003 Sep;14(9):3911-28. Epub 2003 Jul 11.

49.

Interaction between Erbin and a Catenin-related protein in epithelial cells.

Jaulin-Bastard F, Arsanto JP, Le Bivic A, Navarro C, Vély F, Saito H, Marchetto S, Hatzfeld M, Santoni MJ, Birnbaum D, Borg JP.

J Biol Chem. 2002 Jan 25;277(4):2869-75. Epub 2001 Nov 15.

50.

Regulation of inhibitory and activating killer-cell Ig-like receptor expression occurs in T cells after termination of TCR rearrangements.

Vely F, Peyrat M, Couedel C, Morcet J, Halary F, Davodeau F, Romagne F, Scotet E, Saulquin X, Houssaint E, Schleinitz N, Moretta A, Vivier E, Bonneville M.

J Immunol. 2001 Feb 15;166(4):2487-94.

Supplemental Content

Support Center